GlobeNewswire Inc.··Not SpecifiedEvaxion's AI Platform Unlocks Novel Antigen Source for Glioblastoma Vaccines
Evaxion's AI-Immunology platform identifies endogenous retroviruses as glioblastoma vaccine targets, addressing mutational burden challenges. Results presented at AACR in April 2026.
EVAXpersonalized medicinecancer immunotherapy